Biocon Biologics Ltd., a subsidiary of Biocon Ltd, announced today that it has successfully completed its multi-billion-dollar acquisition of the global biosimilars business of its partner Viatris Inc.
Arun Chandavarkar named Biocon Biologics MD
January 22, 2021
Prof Peter Piot joins Biocon Biologics board
Dr Christiane Hamacher has stepped down as the Managing Director of Biocon Biologics Ltd, a subsidiary of Biocon Ltd. She has been replaced with Biocon veteran Dr Arun Chandavarkar.
Dr Hamacher ceased to be a member of the Board of Directors of Biocon Biologics Ltd, effective January 20, 2021. “This decision was taken due to professional differences with the Chairperson on strategic priorities and vision for the company,” the company said in a regulatory filing to the exchanges.
Pursuant to this development, Dr Arun Chandavarkar, member of the board of Biocon Biologics Ltd will take over the mantle of Managing Director, effective January 21, 2021, for a period of up to two years, and Kiran Mazumdar Shaw will be the Executive Chairperson of Biocon Biologics Ltd effective January 21, 2021 until March 31, 2022.